Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa

D. Marin, S. Marktel, M. Bua, R. M. Szydlo, A. Franceschino, I. Nathan, I. Foot, C. Crawley, T. Nakorn Nakorn, E. Olavarria, A. Lennard, A. Neylon, S. G. O'Brien, J. M. Goldman, J. F. Apperley

Research output: Contribution to journal › Article

66 Citations (Scopus)

Abstract

We assessed clinical results in 145 patients with chronic myeloid leukaemia in chronic phase who satisfied criteria for interferon-α failure and were thus eligible for treatment with imatinib at the Hammersmith Hospital. We used univariate and multivariate analyses to develop a risk score based on features defined after treatment for 3 months. We identified a low neutrophil count and poor cytogenetic response (

Original languageEnglish
Pages (from-to)1448-1453
Number of pages6
JournalLeukemia
Volume17
Issue number8
DOIs
Publication statusPublished - Aug 1 2003

Fingerprint

Leukemia, Myeloid, Chronic Phase
Interferon-alpha
Cytogenetics
Interferons
Neutrophils
Multivariate Analysis
Therapeutics
Imatinib Mesylate

Keywords

  • Chronic myeloid leukaemia
  • Cytogenetic response
  • Imatinib mesylate
  • Neutropenia
  • Prognostic factors

ASJC Scopus subject areas

  • Hematology
  • Cancer Research

Cite this

Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa. / Marin, D.; Marktel, S.; Bua, M.; Szydlo, R. M.; Franceschino, A.; Nathan, I.; Foot, I.; Crawley, C.; Nakorn, T. Nakorn; Olavarria, E.; Lennard, A.; Neylon, A.; O'Brien, S. G.; Goldman, J. M.; Apperley, J. F.

In: Leukemia, Vol. 17, No. 8, 01.08.2003, p. 1448-1453.

Research output: Contribution to journal › Article

Marin, D, Marktel, S, Bua, M, Szydlo, RM, Franceschino, A, Nathan, I, Foot, I, Crawley, C, Nakorn, TN, Olavarria, E, Lennard, A, Neylon, A, O'Brien, SG, Goldman, JM & Apperley, JF 2003, 'Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa', Leukemia, vol. 17, no. 8, pp. 1448-1453. https://doi.org/10.1038/sj.leu.2402996
Marin D, Marktel S, Bua M, Szydlo RM, Franceschino A, Nathan I et al. Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa. Leukemia. 2003 Aug 1;17(8):1448-1453. https://doi.org/10.1038/sj.leu.2402996
Marin, D. ; Marktel, S. ; Bua, M. ; Szydlo, R. M. ; Franceschino, A. ; Nathan, I. ; Foot, I. ; Crawley, C. ; Nakorn, T. Nakorn ; Olavarria, E. ; Lennard, A. ; Neylon, A. ; O'Brien, S. G. ; Goldman, J. M. ; Apperley, J. F. / Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa. In: Leukemia. 2003 ; Vol. 17, No. 8. pp. 1448-1453.
@article{fec99156f730465888e622aa3b52389f,
title = "Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa",
abstract = "We assessed clinical results in 145 patients with chronic myeloid leukaemia in chronic phase who satisfied criteria for interferon-α failure and were thus eligible for treatment with imatinib at the Hammersmith Hospital. We used univariate and multivariate analyses to develop a risk score based on features defined after treatment for 3 months. We identified a low neutrophil count and poor cytogenetic response (",
keywords = "Chronic myeloid leukaemia, Cytogenetic response, Imatinib mesylate, Neutropenia, Prognostic factors",
author = "D. Marin and S. Marktel and M. Bua and Szydlo, {R. M.} and A. Franceschino and I. Nathan and I. Foot and C. Crawley and Nakorn, {T. Nakorn} and E. Olavarria and A. Lennard and A. Neylon and O'Brien, {S. G.} and Goldman, {J. M.} and Apperley, {J. F.}",
year = "2003",
month = "8",
day = "1",
doi = "10.1038/sj.leu.2402996",
language = "English",
volume = "17",
pages = "1448--1453",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa

AU - Marin, D.

AU - Marktel, S.

AU - Bua, M.

AU - Szydlo, R. M.

AU - Franceschino, A.

AU - Nathan, I.

AU - Foot, I.

AU - Crawley, C.

AU - Nakorn, T. Nakorn

AU - Olavarria, E.

AU - Lennard, A.

AU - Neylon, A.

AU - O'Brien, S. G.

AU - Goldman, J. M.

AU - Apperley, J. F.

PY - 2003/8/1

Y1 - 2003/8/1

N2 - We assessed clinical results in 145 patients with chronic myeloid leukaemia in chronic phase who satisfied criteria for interferon-α failure and were thus eligible for treatment with imatinib at the Hammersmith Hospital. We used univariate and multivariate analyses to develop a risk score based on features defined after treatment for 3 months. We identified a low neutrophil count and poor cytogenetic response (

AB - We assessed clinical results in 145 patients with chronic myeloid leukaemia in chronic phase who satisfied criteria for interferon-α failure and were thus eligible for treatment with imatinib at the Hammersmith Hospital. We used univariate and multivariate analyses to develop a risk score based on features defined after treatment for 3 months. We identified a low neutrophil count and poor cytogenetic response (

KW - Chronic myeloid leukaemia

KW - Cytogenetic response

KW - Imatinib mesylate

KW - Neutropenia

KW - Prognostic factors

UR - http://www.scopus.com/inward/record.url?scp=0042528659&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042528659&partnerID=8YFLogxK

U2 - 10.1038/sj.leu.2402996

DO - 10.1038/sj.leu.2402996

M3 - Article

C2 - 12886230

AN - SCOPUS:0042528659

VL - 17

SP - 1448

EP - 1453

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 8

ER -

Access to Document